RefleXion Holds Cancer Symposium on Tumor Biology for Personalized Radiotherapy
June 16, 2022
Gathering of leading radiation oncologists and physicists commences with dedication of the Sanjiv “Sam” Gambhir Memorial Learning Center
HAYWARD, Calif., June 16, 2022 – RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy (BgRT)* for all stages of cancer, today announced its first symposium focused on the power of using cancer biology to direct treatment planning and delivery for personalized radiotherapy. The symposium is the inaugural event at the company’s newly dedicated Sanjiv “Sam” Gambhir Memorial Learning Center, to be held on Thursday, June 16.
“We have assembled a group of top-tier radiation oncologists and medical physicists to present their unique approaches to radiotherapy that unleash the power of cancer cell biology to dictate the treatment plan.”
Todd Powell
CEO and President of RefleXion
“We have assembled a group of top-tier radiation oncologists and medical physicists to present their unique approaches to radiotherapy that unleash the power of cancer cell biology to dictate the treatment plan,” said Todd Powell, CEO and president at RefleXion Medical. “These novel treatment paradigms dovetail incredibly well with our breakthrough biology-guided radiotherapy and may one day become the new standards of care.”
More than 65 cancer care professionals from 30 leading cancer programs are expected to attend the symposium to hear keynote speakers, as well as take part in panel presentations and tour the RefleXion manufacturing facility on its Hayward campus.
The event will commence with a dedication of the Sam Gambhir Memorial Learning Center, named after Sanjiv “Sam” Gambhir, M.D., Ph.D., to honor his pioneering contributions to early cancer detection. Dr. Gambhir was a world-renowned physician-scientist, often referred to as the father of molecular imaging. For decades before his death from cancer in 2020, Dr. Gambhir dedicated his career to advancing technologies to catch tumors in their earliest possible stage. He was an advisor and early supporter of RefleXion’s BgRT.
BgRT is the first and only technology designed to use emissions generated by cancer cells in response to an injected radiotracer to guide the delivery of radiotherapy. RefleXion’s BgRT received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for use in lung tumors because of its potential to detect and then immediately treat moving targets. The company aims to one day scale BgRT to treat all visible cancer sites to create a new treatment option for patients with metastatic disease.
About RefleXion Medical
RefleXion is a privately-held company developing the first biology-guided radiotherapy system, a significant change in strategy from single tumor therapy to the ability to one day treat multiple tumors in the same treatment session in cancers that have metastasized. Currently, the RefleXion X1 machine is cleared for the delivery of stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT). The company is also developing BgRT, which incorporates positron-emission tomography (PET) imaging data to enable tumors to continuously signal their location. The BgRT technology will synchronize these data with the linear accelerator to direct radiotherapy to tumors with subsecond latency.
*The RefleXion® X1 is cleared for SBRT/SRS/IMRT. BgRT is pending regulatory review and is not commercially available.
Media Contacts
Amy Cook
acook@reflexion.com
925-200-2125
